+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease



Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease



Hemoglobin 36(4): 323-332



There is limited data on the efficacy of hydroxyurea (HU) in Indian sickle cell anemia patients who have severe manifestations despite high fetal hemoglobin (Hb F). Sixty sickle cell anemia children (5-18 years) with more than three episodes of vasoocclusive crises or blood transfusions per year were randomized to receive HU (n = 30) or placebo (n = 30) therapy. Fixed dose (10 mg/kg/day) of HU was administered for 18 months and the patients were followed-up monthly with clinical assessment and laboratory monitoring. In the HU group, hemoglobin (Hb) and Hb F levels increased significantly along with a significant decrease in the number of painful crises, blood transfusion requirements and hospitalizations compared to the placebo group. No major adverse events were observed in this study. In conclusion, low-fixed dose HU therapy was effective for the treatment of Indian sickle cell anemia children. However, there is a need for long-term studies to evaluate the efficacy and toxicity in a larger number of Indian sickle cell anemia patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054184257

Download citation: RISBibTeXText

PMID: 22734586

DOI: 10.3109/03630269.2012.697948


Related references

Hydroxyurea therapy in children severely affected with sickle cell disease. Journal Of Pediatrics. 128(6): 820-828, 1996

Hydroxyurea therapy in severely affected children with sickle cell disease. Pediatric Research 35(4 PART 2): 163A, 1994

Hydroxyurea treatment in severely affected sickle cell disease children. Beuzard, Y, Lubin, B, Rosa, J, INSERM Colloquium; Sickle cell disease and thalassaemias: New trends in therapy, Colloque INSERM; Sickle cell disease and thalassaemias: New trends in therapy 171-172, 1995

A pilot study of hydroxyurea treatment of severely affected children with sickle cell disease. Pediatric Research 33(4 PART 2): 147A, 1993

Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?. Pediatric Blood and Cancer 63(5): 844-847, 2016

Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia:A single centre experience. Indian Pediatrics 50(10): 929-933, 2013

Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian Pediatrics 50(10): 929-933, 2014

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 19(4): 313-318, 1997

Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective. European Journal of Haematology 90(6): 519-524, 2013

"Maximum Tolerated Dose" versus "Fixed Low-Dose" Hydroxyurea for Treatment of Adults with Sickle Cell Anemia. American Journal of Hematology 2019, 2019

Fixed Low-Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Anemia in Nigeria. American Journal of Hematology 2018, 2018

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103(6): 2039-2045, 2003

Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells, Molecules and Diseases 42(1): 25-31, 2008

Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?. Pediatric Blood and Cancer 62(6): 929-930, 2015

Hydroxyurea for children with sickle cell disease. Pediatric Clinics of North America 55(2): 483-501, X, 2008